<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">lvrach</journal-id><journal-title-group><journal-title xml:lang="ru">Лечащий Врач</journal-title><trans-title-group xml:lang="en"><trans-title>Lechaschi Vrach</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-5175</issn><issn pub-type="epub">2687-1181</issn><publisher><publisher-name>ООО «Издательство "Открытые системы"»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.51793/OS.2025.28.8.002</article-id><article-id custom-type="elpub" pub-id-type="custom">lvrach-1445</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ГАСТРОЭНТЕРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>GASTROENTEROLOGY</subject></subj-group></article-categories><title-group><article-title>Особенности состава и коррекция  кишечной микробиоты метапребиотиком как один из компонентов комплексного лечения пациенток с аутоиммунным тиреоидитом</article-title><trans-title-group xml:lang="en"><trans-title>Features of the composition and correction of gut microbiota with metaprebiotic as one of the components of complex treatment of patients with autoimmune thyroiditis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3138-8410</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Стуров</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sturov</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Стуров Николай Владимирович, к.м.н., заведующий кафедрой общей врачебной практики</p><p>117198, Россия, Москва, ул. Миклухо-Маклая, 6</p></bio><bio xml:lang="en"><p>Nikolay V. Sturov, Cand. of Sci. (Med.), Head of the Department of General Medical Practice</p><p>6 Miklukho-Maklaya str., Moscow, 117198</p></bio><email xlink:type="simple">sturov_nv@rudn.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5729-4658</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Костенко</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kostenko</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Костенко Алина Александровна, аспирантка кафедры общей врачебной практики</p><p>117198, Россия, Москва, ул. Миклухо-Маклая, 6</p></bio><bio xml:lang="en"><p>Alina A. Kostenko, PhD student at the Department of General Medical Practice</p><p>6 Miklukho-Maklaya str., Moscow, 117198</p></bio><email xlink:type="simple">alinakost94@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5710-0414</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шимкевич</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Shimkevich</surname><given-names>E. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шимкевич Екатерина Михайловна, старший преподаватель кафедры медицинской информатики и телемедицины</p><p>117198, Россия, Москва, ул. Миклухо-Маклая, 6</p></bio><bio xml:lang="en"><p>Ekaterina M. Shimkevich, Senior Lecturer at the Department of Medical Informatics and Telemedicine</p><p>6 Miklukho-Maklaya str., Moscow, 117198</p></bio><email xlink:type="simple">shimkevich_em@rudn.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российский университет дружбы народов</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Peoples' Friendship University of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>19</day><month>08</month><year>2025</year></pub-date><volume>1</volume><issue>7-8</issue><fpage>17</fpage><lpage>21</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Стуров Н.В., Костенко А.А., Шимкевич Е.М., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Стуров Н.В., Костенко А.А., Шимкевич Е.М.</copyright-holder><copyright-holder xml:lang="en">Sturov N.V., Kostenko A.A., Shimkevich E.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.lvrach.ru/jour/article/view/1445">https://journal.lvrach.ru/jour/article/view/1445</self-uri><abstract><sec><title>Введение</title><p>Введение. В последние годы пристальное внимание исследователей приковано к изучению состава микробиоты кишечника и его влиянию на течение аутоиммунных заболеваний.</p></sec><sec><title>Цель работы</title><p>Цель работы. Изучить количественные и качественные характеристики микробиоты кишечника у молодых женщин, страдающих аутоиммунным тиреоидитом, а также оценить эффективность метапребиотика у пациенток с данным заболеванием и дисбиозом кишечника.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В данном исследовании мы изучили образцы фекальной микробиоты и анкетировали на предмет клинических проявлений дисбиоза кишечника 25 женщин с аутоиммунным тиреоидитом в возрасте 18-43 лет, получающих заместительную терапию левотироксином натрия, и 10 здоровых женщин. После определения состава микробиоты кишечника методом газовой хроматографии-масс-спектрометрии 10 женщин с аутоиммунным тиреоидитом и клиническими симптомами дисбиоза получали лечение метапребиотиком (500 мг) по 2 капсулы 3 раза в сутки в течение 14 дней с повторным исследованием микробиоты кишечника и анкетированием.</p></sec><sec><title>Результаты</title><p>Результаты. При сравнении двух групп пациенток с аутоиммунным тиреоидитом с жалобами на дисбиоз кишечника и контрольной группы были получены отличия в виде увеличения следующих представителей: Streptococcus mutans (анаэробный), Clostridium perfringens, Lactobacillus spp., Peptostreptococcus anaerobius 18 623 (p &lt; 0,005). После курса лечения метапребиотиком наблюдалось снижение представителей Streptococcus mutans (анаэробные) и Clostridium perfringens. Кроме того, наблюдалось уменьшение клинических проявлений дисбиоза кишечника, таких как запор, боли в животе и метеоризм, однако у части пациенток сохранялись жалобы на сухость кожных покровов, головные боли и общую слабость, но данные симптомы нельзя убедительно связать с дисбиозом кишечника.</p></sec><sec><title>Заключение</title><p>Заключение. Дальнейшее определение состава микробиоты кишечника и анализ полученных данных позволят идентифицировать группы диагностически значимых микроорганизмов, которые ассоциированы с аутоиммунным тиреоидитом, и их воздействие на микробиоту кишечника, а также инициировать изучение влияния пре- и пробиотиков на течение аутоиммунных заболеваний путем назначения пробиотических добавок отдельно или в сочетании с пребиотиками. В будущем это может рассматриваться как один из ключевых компонентов лечения аутоиммунного тиреоидита совместно с гормональной терапией левотироксином.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. In recent years, researchers pay close attention to studying the composition of the gut microbiota and its effect on the course of autoimmune diseases.</p></sec><sec><title>Objectives</title><p>Objectives. To study the quantitative and qualitative characteristics of gut microbiota of young women suffering from autoimmune thyroiditis, as well as to evaluate the effectiveness of metaprebiotic administration for patients with autoimmune thyroiditis and intestinal dysbiosis.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. In this study, we examined fecal microbiota samples and surveyed 25 women with autoimmune thyroiditis aged 18-43 years receiving levothyroxine sodium replacement therapy and 10 healthy women for clinical manifestations of intestinal dysbiosis. After determining the composition of gut microbiota by gas chromatography-mass spectrometry, 10 women with autoimmune thyroiditis and clinical symptoms of dysbiosis were treated with metaprebiotic at a dose of 500 mg 2 capsules 3 times a day for 14 days with repeated examination of gut microbiota and a questionnaire.</p></sec><sec><title>Results</title><p>Results. When comparing two groups of patients with autoimmune thyroiditis with complaints of intestinal dysbiosis and the control group, differences were obtained in the form of an increase in the following representatives: Streptococcus mutans (anaerobic), Clostridium perfringens, Lactobacillus spp., Peptostreptococcus anaerobius 18 623 (p &lt; 0,005). After a course of meta-prebiotic treatment, there was a decrease in representatives of Streptococcus mutans (anaerobic) and Clostridium perfringens. There was also a decrease of the clinical manifestations of intestinal dysbiosis, such as complaints of constipation, abdominal pain and flatulence. However, some patients continued to complain of dry skin, headaches and general weakness, but these symptoms cannot be convincingly linked to intestinal dysbiosis.</p></sec><sec><title>Conclusion</title><p>Conclusion. Further determination of the gut microbiota composition and analysis of the data obtained will allow identifying groups of diagnostically significant microorganisms that are associated with autoimmune thyroiditis and their effect on gut microbiota, as well as studying the effect of pre- and probiotics on the course of autoimmune diseases by prescribing probiotic supplements separately or in combination with prebiotics in the future can be considered as one of the key components of autoimmune thyroiditis treatment in combination with hormonal therapy with levothyroxine.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>аутоиммунный тиреоидит</kwd><kwd>гипотиреоз</kwd><kwd>аутоиммунные заболевания</kwd><kwd>микробиота кишечника</kwd><kwd>дисбиоз кишечника</kwd><kwd>метапребиотик</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Autoimmune thyroiditis</kwd><kwd>hypothyroidism</kwd><kwd>autoimmune diseases</kwd><kwd>gut microbiota</kwd><kwd>intestinal dysbiosis</kwd><kwd>metaprebiotic</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Moshkelgosha S., Verhasselt H. L., Masetti G., et al.; INDIGO consortium. Modulating gut microbiota in a mouse model of Graves' orbitopathy and its impact on induced disease. Microbiome. 2021; 1 (9): 45. DOI: 10.1186/s40168-020-00952-4. PMID: 33593429; PMCID: PMC7888139.</mixed-citation><mixed-citation xml:lang="en">Moshkelgosha S., Verhasselt H. L., Masetti G., et al.; INDIGO consortium. Modulating gut microbiota in a mouse model of Graves' orbitopathy and its impact on induced disease. Microbiome. 2021; 1 (9): 45. DOI: 10.1186/s40168-020-00952-4. PMID: 33593429; PMCID: PMC7888139.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Vatanen T., Kostic A. D., d'Hennezel E., et al.; DIABIMMUNE Study Group; Xavier R. J. Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans. Cell. 2016; 4 (165): 842-853. DOI: 10.1016/j.cell.2016.04.007. PMID: 27133167; PMCID: PMC4950857.</mixed-citation><mixed-citation xml:lang="en">Vatanen T., Kostic A. D., d'Hennezel E., et al.; DIABIMMUNE Study Group; Xavier R. J. Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans. Cell. 2016; 4 (165): 842-853. DOI: 10.1016/j.cell.2016.04.007. PMID: 27133167; PMCID: PMC4950857.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Astbury S., Atallah E., Vijay A., et al. Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis. Gut Microbes. 2020; 3 (11): 569-580. DOI: 10.1080/19490976.2019.1681861. PMID: 31696774; PMCID: PMC7524262.</mixed-citation><mixed-citation xml:lang="en">Astbury S., Atallah E., Vijay A., et al. Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis. Gut Microbes. 2020; 3 (11): 569-580. DOI: 10.1080/19490976.2019.1681861. PMID: 31696774; PMCID: PMC7524262.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Fernandez-Tome S., Ortega Moreno L., Chaparro M., et al. Gut Microbiota and Dietary Factors as Modulators of the Mucus Layer in Inflammatory Bowel Disease. Int J Mol Sci. 2021; 19 (22): 10224. DOI: 10.3390/ijms221910224. PMID: 34638564; PMCID: PMC8508624.</mixed-citation><mixed-citation xml:lang="en">Fernandez-Tome S., Ortega Moreno L., Chaparro M., et al. Gut Microbiota and Dietary Factors as Modulators of the Mucus Layer in Inflammatory Bowel Disease. Int J Mol Sci. 2021; 19 (22): 10224. DOI: 10.3390/ijms221910224. PMID: 34638564; PMCID: PMC8508624.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Yang Y., Torchinsky M. B., Gobert M., et al. Focused specificity of intestinal TH17 cells towards commensal bacterial antigens. Nature. 2014; 7503 (510): 152-156. DOI: 10.1038/nature13279. PMID: 24739972; PMCID: PMC4128479.</mixed-citation><mixed-citation xml:lang="en">Yang Y., Torchinsky M. B., Gobert M., et al. Focused specificity of intestinal TH17 cells towards commensal bacterial antigens. Nature. 2014; 7503 (510): 152-156. DOI: 10.1038/nature13279. PMID: 24739972; PMCID: PMC4128479.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Groele L., Szajewska H., Szalecki M., et al. Lack of Effect of Lactobacillus Rhamnosus GG and Bifidobacterium Lactis Bb12 on Beta-Cell Function in Children With Newly Diagnosed Type 1 Diabetes: A Randomised Controlled Trial. BMJ Open Diabetes Res Care. 2021; 1 (9): e001523. DOI: 10.1136/bmjdrc-2020-001523.</mixed-citation><mixed-citation xml:lang="en">Groele L., Szajewska H., Szalecki M., et al. Lack of Effect of Lactobacillus Rhamnosus GG and Bifidobacterium Lactis Bb12 on Beta-Cell Function in Children With Newly Diagnosed Type 1 Diabetes: A Randomised Controlled Trial. BMJ Open Diabetes Res Care. 2021; 1 (9): e001523. DOI: 10.1136/bmjdrc-2020-001523.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Cayres L. C. F., de Salis L. V. V., Rodrigues G. S. P., et al. Detection of Alterations in the Gut Microbiota and Intestinal Permeability in Patients With Hashimoto Thyroiditis. Front Immunol. 2021; Vol. 12: Article 579140. DOI: 10.3389/fimmu.2021.579140. PMID: 33746942; PMCID: PMC7973118.</mixed-citation><mixed-citation xml:lang="en">Cayres L. C. F., de Salis L. V. V., Rodrigues G. S. P., et al. Detection of Alterations in the Gut Microbiota and Intestinal Permeability in Patients With Hashimoto Thyroiditis. Front Immunol. 2021; Vol. 12: Article 579140. DOI: 10.3389/fimmu.2021.579140. PMID: 33746942; PMCID: PMC7973118.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Su X., Zhao Y., Li Y., et al. Gut dysbiosis is associated with primary hypothyroidism with interaction on gut-thyroid axis. Clin Sci (Lond). 2020; 12 (134): 1521-1535. DOI: 10.1042/CS20200475. PMID: 32519746.</mixed-citation><mixed-citation xml:lang="en">Su X., Zhao Y., Li Y., et al. Gut dysbiosis is associated with primary hypothyroidism with interaction on gut-thyroid axis. Clin Sci (Lond). 2020; 12 (134): 1521-1535. DOI: 10.1042/CS20200475. PMID: 32519746.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao H., Yuan L., Zhu D., et al. Alterations and Mechanism of Gut Microbiota in Graves' Disease and Hashimoto's Thyroiditis. Pol J Microbiol. 2022; 2 (71): 173-189. DOI: 10.33073/pjm-2022-016. PMID: 35675824; PMCID: PMC9252144.</mixed-citation><mixed-citation xml:lang="en">Zhao H., Yuan L., Zhu D., et al. Alterations and Mechanism of Gut Microbiota in Graves' Disease and Hashimoto's Thyroiditis. Pol J Microbiol. 2022; 2 (71): 173-189. DOI: 10.33073/pjm-2022-016. PMID: 35675824; PMCID: PMC9252144.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y., Alookaran J. J., Rhoads J. M. Probiotics in Autoimmune and Inflammatory Disorders. Nutrients. 2018; 10 (10): 1537. DOI: 10.3390/nu10101537. PMID: 30340338; PMCID: PMC6213508.</mixed-citation><mixed-citation xml:lang="en">Liu Y., Alookaran J. J., Rhoads J. M. Probiotics in Autoimmune and Inflammatory Disorders. Nutrients. 2018; 10 (10): 1537. DOI: 10.3390/nu10101537. PMID: 30340338; PMCID: PMC6213508.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lin B., Zhao F., Liu Y., et al. Randomized Clinical Trial: Probiotics Alleviated Oral-Gut Microbiota Dysbiosis and Thyroid Hormone Withdrawal-Related Complications in Thyroid Cancer Patients Before Radioiodine Therapy Following Thyroidectomy. Front Endocrinol (Lausanne). 2022; Vol. 13: Article 834674. DOI: 10.3389/fendo.2022.834674. PMID: 35350100; PMCID:</mixed-citation><mixed-citation xml:lang="en">Lin B., Zhao F., Liu Y., et al. Randomized Clinical Trial: Probiotics Alleviated Oral-Gut Microbiota Dysbiosis and Thyroid Hormone Withdrawal-Related Complications in Thyroid Cancer Patients Before Radioiodine Therapy Following Thyroidectomy. Front Endocrinol (Lausanne). 2022; Vol. 13: Article 834674. DOI: 10.3389/fendo.2022.834674. PMID: 35350100; PMCID:</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Foye O. T., Huang I. F., Chiou C. C., et al. Early administration of probiotic Lactobacillus acidophilus and/or prebiotic inulin attenuates pathogenmediated intestinal inflammation and Smad 7 cell signaling. FEMS Immunol Med Microbiol. 2012; 3 (65): 467-480. DOI: 10.1111/j.1574695X.2012.00978.x. PMID: 22524476; PMCID: PMC4015462.</mixed-citation><mixed-citation xml:lang="en">Foye O. T., Huang I. F., Chiou C. C., et al. Early administration of probiotic Lactobacillus acidophilus and/or prebiotic inulin attenuates pathogenmediated intestinal inflammation and Smad 7 cell signaling. FEMS Immunol Med Microbiol. 2012; 3 (65): 467-480. DOI: 10.1111/j.1574695X.2012.00978.x. PMID: 22524476; PMCID: PMC4015462.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Wang B., Xu Y., Hou X., et al. Small Intestinal Bacterial Overgrowth in Subclinical Hypothyroidism of Pregnant Women. Front Endocrinol (Lausanne). 2021; Vol. 12: Article 604070. DOI: 10.3389/fendo.2021.604070. PMID: 34108932; PMCID: PMC8181748.</mixed-citation><mixed-citation xml:lang="en">Wang B., Xu Y., Hou X., et al. Small Intestinal Bacterial Overgrowth in Subclinical Hypothyroidism of Pregnant Women. Front Endocrinol (Lausanne). 2021; Vol. 12: Article 604070. DOI: 10.3389/fendo.2021.604070. PMID: 34108932; PMCID: PMC8181748.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Yaylali O., Kirac S., Yilmaz M., et al. Does hypothyroidism affect gastrointestinal motility? Gastroenterol Res Pract. 2009; Article 529802. DOI: 10.1155/2009/529802.</mixed-citation><mixed-citation xml:lang="en">Yaylali O., Kirac S., Yilmaz M., et al. Does hypothyroidism affect gastrointestinal motility? Gastroenterol Res Pract. 2009; Article 529802. DOI: 10.1155/2009/529802.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">P atil A. D. Link between hypothyroidism and small intestinal bacterial overgrowth. Indian J Endocrinol Metab. 2014; 3 (18): 307-309. DOI: 10.4103/2230-8210.131155. PMID: 24944923; PMCID: PMC4056127.</mixed-citation><mixed-citation xml:lang="en">P atil A. D. Link between hypothyroidism and small intestinal bacterial overgrowth. Indian J Endocrinol Metab. 2014; 3 (18): 307-309. DOI: 10.4103/2230-8210.131155. PMID: 24944923; PMCID: PMC4056127.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
